Capital Fund Management (CFM)
PACB icon

Capital Fund Management (CFM)’s Pacific Biosciences PACB Stock Holding History

Capital Fund Management (CFM)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-76,000
Closed -$285K – 2102
2024
Q1 		$285K Sell
76,000
-70,100
-48% -$410K ﹤0.01% 1922
2023
Q4 		$1.43M Buy
146,100
+68,200
+88% +$558K ﹤0.01% 1687
2023
Q3 		$650K Buy
77,900
+44,500
+133% +$509K ﹤0.01% 1750
2023
Q2 		$444K Sell
33,400
-21,300
-39% -$259K ﹤0.01% 1584
2023
Q1 		$633K Buy
+54,700
New +$544K ﹤0.01% 1402
2022
Q1 		– Sell
-15,100
Closed -$309K – 1707
2021
Q4 		$309K Sell
15,100
-8,200
-35% -$198K ﹤0.01% 1523
2021
Q3 		$595K Sell
23,300
-8,600
-27% -$255K ﹤0.01% 1329
2021
Q2 		$1.12M Buy
31,900
+19,300
+153% +$561K 0.01% 1134
2021
Q1 		$420K Buy
+12,600
New +$441K ﹤0.01% 1170

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Capital Fund Management (CFM)'s PACB Position: Q4 2022 in Review

Capital Fund Management (CFM) sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 83,468 shares — an estimated $485K sold.

Capital Fund Management (CFM) first reported a position in PACB in Q2 2014 and held it in 3 quarters. The position peaked at $526K in Q2 2016. 236 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

  • Capital Fund Management (CFM) reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 83,468 Pacific Biosciences shares in Q4 2022, an estimated $485K.
  • Capital Fund Management (CFM) first reported a position in Pacific Biosciences in Q2 2014 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Pacific Biosciences position peaked at $526K in Q2 2016.
  • 236 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2022, filed 13 Feb 2023.